UCT 001024
Alternative Names: UCT-001024Latest Information Update: 23 Jun 2023
At a glance
- Originator 1200 Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Solid tumours in USA (unspecified route), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 09 Nov 2022 1200 Pharma files for patent protection with US FDA for "Select kras g12c inhibitors and uses thereof" worldwide